There were 19 press releases posted in the last 24 hours and 147,866 in the last 365 days.

Optic Neuropathy Pipeline Review H2 2016– Analysis Of Key Players And Enlists All Their Major And Minor Projects 2016

PUNE, INDIA, September 22, 2016 /EINPresswire.com/ -- Optic Neuropathy Therapeutic Market 2016

Complete Report Details @ https://www.wiseguyreports.com/reports/649774-optic-neuropathy-pipeline-review-h2-2016

The, ‘Optic Neuropathy - Pipeline Review, H2 2016’, provides an overview of the Optic Neuropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Optic Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Optic Neuropathy and features dormant and discontinued projects.

For more information or any query mail at sales@wiseguyreports.com

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Get a Sample Report @ https://www.wiseguyreports.com/sample-request/649774-optic-neuropathy-pipeline-review-h2-2016

Scope
- The report provides a snapshot of the global therapeutic landscape of Optic Neuropathy
- The report reviews pipeline therapeutics for Optic Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Optic Neuropathy therapeutics and enlists all their major and minor projects
- The report assesses Optic Neuropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Optic Neuropathy

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Optic Neuropathy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Optic Neuropathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents – Major Key Points

#Companies Involved in Therapeutics Development:
Optic Neuropathy - Companies Involved in Therapeutics Development 17
Amgen Inc. 17
BioAxone BioSciences, Inc. 18
Inotek Pharmaceuticals Corporation 19
Ironwood Pharmaceuticals, Inc. 20
PharmatrophiX, Inc. 21
Quark Pharmaceuticals, Inc. 22
Regenera Pharma Ltd. 23
Optic Neuropathy - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
BA-240 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
IWP-953 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
LM-22A4 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35

…….CONTUNUED

For more information or any query mail at sales@wiseguyreports.com

Get Exclusive Discount On This Report @ https://www.wiseguyreports.com/check-discount/649774-optic-neuropathy-pipeline-review-h2-2016

ABOUT US:
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here